NanoBio Presents Key Data on the Use of Nanoemulsions to Treat Burn Wound Infections

Study results being presented at ICAAC 2009

ANN ARBOR, Mich.--(BUSINESS WIRE)--Sep 14, 2009 - NanoBio Corporation today announced compelling preclinical data for NB-201, a nanoemulsion-based topical lotion for the treatment of burn wounds. In preclinical studies, NB-201 dramatically reduced the severity of burn wound infections as well as inflammation following thermal injuries. The research was conducted at the University of Michigan Medical School in Ann Arbor as a collaborative effort between the University and NanoBio. The study results are being presented at the 2009 Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) in San Francisco, Calif.

In the study, partial thickness burn wounds in rats were inoculated with Pseudomonas aeruginosa bacteria, and then were treated 8 and 16 hours later with NB-201, placebo, 5% Sulfamylon and a saline control. Treatment with NB-201 resulted in a one-thousand fold reduction of bacterial growth as compared to control (p<0.001). In addition, NB-201 demonstrated a greater reduction of bacterial counts than Sulfamylon, a common topical antimicrobial currently used in the treatment of burn injuries.

“NB-201 clearly demonstrated an ability to eradicate bacteria in a burn wound. As importantly, it also resulted in reduction of proinflammatory cytokines and local tissue inflammation which was coupled with a reduction in capillary leak and local tissue edema,” said Mark R. Hemmila, MD Associate Professor of Surgery at the University of Michigan Medical School. “NB-201 has the potential to be very useful in helping prevent infection to the damaged area of the wound and to reduce early post-burn inflammation.”

These findings indicate the potential benefits of NB-201 for treating burn wounds, by both reducing bacterial growth and mitigating a local inflammatory response which can lead to ongoing loss of intravascular fluid, systemic inflammation and end-organ dysfunction. The underlying technology for NB-201 is NanoBio's NanoStat™ platform technology, which employs high-energy, oil-in-water emulsion droplets that are manufactured at a size of 200-600 nanometers.

About NanoBio

NanoBio® Corporation is a privately held biopharmaceutical company focused on developing and commercializing dermatological products, anti-infective treatments and intranasal vaccines derived from its patented NanoStat™ technology platform. The company's lead dermatology and anti-infective product candidates include treatments for herpes labialis (cold sores), onychomycosis (nail fungus), tinea capitis, acne, molluscum contagiosum and cystic fibrosis. The company's headquarters and laboratory facilities are located in Ann Arbor, Michigan. NanoBio is a spin-off from the University of Michigan and holds the exclusive global license to the nanoemulsion platform technology.

 

Contact: NanoBio Corporation
John Coffey, 734-302-9107
Vice President, Business Development
john.coffey@nanobio.com
or
Schwartz Communications
Andrea tenBroek or Laura Coluci, 781-684-0770
nanobio@schwartz-pr.com

 

 

Posted: September 2009

View comments

Hide
(web1)